evidence-based extrapolation for biosimilars
Published 4 years ago • 90 plays • Length 8:21Download video MP4
Download video MP3
Similar videos
-
0:51
fast facts about extrapolation for biosimilars - amgen science
-
1:13
dr. cuellar on concerns with extrapolating data for biosimilars
-
4:36
the extrapolation of biosimilar indications: understand the practical implications
-
20:06
biologics and biosimilars: extrapolation of indications – information for healthcare providers
-
3:36
the extrapolation of indications
-
6:30
biosimilars: extrapolation & rational medicine use
-
4:34
extrapolation - safely approving biosimilars for different indications
-
25:00
biosimilars extrapolation and issues around interchangeability
-
5:20
data requirements for biosimilars
-
1:14
robert rifkin, md, on the impact of extrapolation and interchangeability on biosimilar use
-
24:30
biosimilars extrapolation and issues around interchangeability
-
2:47
biosimilars: approval process
-
2:21
what are biosimilars?
-
2:04
biosimilars: the path to approval
-
8:03
navigating biosimilars: extrapolation, naming, substitution (blue line)
-
13:32
01 introduction to biosimilars
-
0:56
quality assessment of biologics and biosimilars at atomic level
-
1:44
fast facts about the regulatory approval pathway for biosimilars – amgen science
-
19:39
02 the us biosimilars regulatory pathway